To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.
This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer patients without venous thromboembolism(VTE) are included. The selected patients were randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL, subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The incidence of VTE , the risks of bleeding and overall survival in two groups of patients are studied at different time points.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
272
Incidence of venous thromboembolism
Time frame: 12 weeks
Incidence of bleeding
Time frame: During 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Department of Oncology，Southwest Hospital
Chongqing, Chongqing Municipality, China
RECRUITINGThe Department of Pulmonary and Critical Care Medicine,Southwest Hospital
Chongqing, Chongqing Municipality, China
RECRUITINGThe Department of Oncology，Ohtsubo Hospital
Chongqing, Chongqing Municipality, China
RECRUITINGThe Department of Oncology，Fuling Central Hospital
Chongqing, Chongqing Municipality, China
RECRUITINGThe Department of Oncology，Central Hospital
Xinxiang, Henan, China
RECRUITINGThe Department of Oncology，People's Hospital
Zhengzhou, Henan, China
RECRUITINGThe Department of Pulmonary and Critical Care Medicine,Cancer Hospital
Zhengzhou, Henan, China
RECRUITINGThe Department of Oncology，Henan University Affiliated Yihe Hospital
Zhengzhou, Henan, China
RECRUITINGThe Department of Oncology，Cancer Hospital
Baotou, Inner Mongolia, China
RECRUITINGThe Department of Oncology，Northern Hospital
Baotou, Inner Mongolia, China
RECRUITING...and 14 more locations